CO2023001975A2 - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- CO2023001975A2 CO2023001975A2 CONC2023/0001975A CO2023001975A CO2023001975A2 CO 2023001975 A2 CO2023001975 A2 CO 2023001975A2 CO 2023001975 A CO2023001975 A CO 2023001975A CO 2023001975 A2 CO2023001975 A2 CO 2023001975A2
- Authority
- CO
- Colombia
- Prior art keywords
- sarm1
- sarm1 inhibitors
- inhibitors
- treating
- present disclosure
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción proporciona compuestos y métodos útiles para inhibir SARM1 y/o tratar y/o prevenir la degeneración axonal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023001975A2 true CO2023001975A2 (es) | 2023-03-07 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0001975A CO2023001975A2 (es) | 2020-08-24 | 2023-02-22 | Inhibidores de sarm1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220056013A1 (es) |
| EP (1) | EP4200293A1 (es) |
| JP (2) | JP7349046B2 (es) |
| KR (1) | KR20230057396A (es) |
| AU (1) | AU2021333558B2 (es) |
| BR (1) | BR112023002575A2 (es) |
| CA (1) | CA3189181A1 (es) |
| CL (1) | CL2023000525A1 (es) |
| CO (1) | CO2023001975A2 (es) |
| CR (1) | CR20230113A (es) |
| DO (1) | DOP2023000038A (es) |
| EC (1) | ECSP23012981A (es) |
| IL (1) | IL300586A (es) |
| MX (1) | MX2023002256A (es) |
| PE (1) | PE20230737A1 (es) |
| TW (2) | TWI786777B (es) |
| WO (1) | WO2022046606A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022031736A1 (en) | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| EP4214197A1 (en) | 2020-09-16 | 2023-07-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| US20240102018A1 (en) * | 2022-07-21 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Oligonucleotide compositions and methods thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7044789B2 (ja) | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用 |
| US20200095241A1 (en) * | 2016-12-22 | 2020-03-26 | Bayer Cropscience Aktiengesellschaft | Substituted 1,2,4-thiadiazolylpyrrolones and 1,2,4-thiadiazolylhydantoins and salts thereof and use thereof as herbicides |
| BR112020012651A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos |
| CN112867489A (zh) * | 2018-06-07 | 2021-05-28 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN112839648A (zh) | 2018-06-07 | 2021-05-25 | 达萨玛治疗公司 | Sarm1抑制剂 |
| US20220098180A1 (en) * | 2019-01-30 | 2022-03-31 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2022031736A1 (en) * | 2020-08-04 | 2022-02-10 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 US US17/408,956 patent/US20220056013A1/en active Pending
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 AU AU2021333558A patent/AU2021333558B2/en active Active
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Search and Examination
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en active Application Filing
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
-
2023
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP2024016014A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021333558A1 (en) | 2023-03-02 |
| WO2022046606A1 (en) | 2022-03-03 |
| MX2023002256A (es) | 2023-03-17 |
| DOP2023000038A (es) | 2023-03-15 |
| TW202334117A (zh) | 2023-09-01 |
| EP4200293A1 (en) | 2023-06-28 |
| JP7349046B2 (ja) | 2023-09-21 |
| KR20230057396A (ko) | 2023-04-28 |
| ECSP23012981A (es) | 2023-03-31 |
| AU2021333558B2 (en) | 2024-02-22 |
| BR112023002575A2 (pt) | 2023-03-07 |
| PE20230737A1 (es) | 2023-05-03 |
| IL300586A (en) | 2023-04-01 |
| JP2024016014A (ja) | 2024-02-06 |
| TWI786777B (zh) | 2022-12-11 |
| TW202214597A (zh) | 2022-04-16 |
| JP2023535236A (ja) | 2023-08-16 |
| US20220056013A1 (en) | 2022-02-24 |
| CA3189181A1 (en) | 2022-03-03 |
| CL2023000525A1 (es) | 2023-09-15 |
| CR20230113A (es) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23012981A (es) | Inhibidores de sarm1 | |
| ECSP22053394A (es) | Inhibidores de sarm1 | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| BR112018017086A2 (pt) | derivados de pirrolidina espiro-condensada como inibidores de enzimas desubiquitilantes (dub) | |
| MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| WO2018195110A8 (en) | Regulation of ran translation by pkr and eif2a-p pathways | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| BR112018068027A2 (pt) | método para tratar câncer em um paciente e composição farmacêutica | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| CO2019001402A2 (es) | Método para prevenir o tratar la pérdida de la audición | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
| BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma |